Intralesional Interferon α-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited

Dermatologic Surgery

Volumn 30, Issue 1, 2004, Pages 116-120

  Kim, Karen H ^a,b   Yavel, Regina M ^a   Gross, Victoria L ^a   Brody, Neil ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CRYOTHERAPY; DESICCATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; SKIN NEOPLASMS;

EID: 0842333115     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30020.x     Document Type: Article

References (29)

1. Isaacs A, Lindenmann J. Virus interference: I: the interferon. Proc R Soc Lond (Biol) 1957;147:258-67.
2. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23:694-700.
3. Buechner SA. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. J Am Acad Dermatol 1991;24:731-4.
4. DiLorenzo PA, Goodman N, Lansville F, Markel W. Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-2b. J Am Acad Dermatol 1994;31:109-11.
5. Edwards L, Berman B, Rapini RP, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol 1992;128:1486-9.
6. Greenway HR, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986;15:437-43.
7. Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7.
8. Healsmith MF, Berth-Jones J, Fletcher A. Treatment of basal cell carcinoma with intralesional interferon alpha-2b. J R Soc Med 1991;84:524-6.
9. Edwards L, Levine N, Smiles KA. The effect of topical interferon alpha-2b on actinic keratoses. J Dermatol Surg Oncol 1990; 16:446-9.
10. Chimenti S, Peris K, Di Cristofaro S, Fargnoli MC, Torlone G. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 1995;190:214-7.
11. Stenquist B, Wennberg AM, Gisslen H, Larko O. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992; 27:65-9.
12. Boneschi V, Brambilla L, Chiappino G, Mozzanica N, Finzi AF. Intralesional alpha 2b recombinant interferon for basal cell carcinomas. Int J Dermatol 1991;30:220-4.
13. Wickramasinghe MB, Hindson TC, Wacks H. Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol 1989;20:71-4.
14. Greenway HT, Cornell RC. Interferon: coming of age. Arch Dermatol 1990;126:1080-2.
15. Ikic D, Padovan I, Pipic N, et al. Treatment of squamous cell carcinoma with interferon. Int J Dermatol 1991;30:58-61.
16. Pfeffer LM, Dinarello CA, Heberman RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-99.
17. 1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 1980;77:1471-5.
18. Borden EC. Interferons: rationale for clinical trials in neoplastic disease. Ann Intern Med 1979;91:472-9.
19. Gresser I. On the mechanism of the antitumor effects of interferon. Tex Rep Biol Med 1977;35:394-8.
20. Gresser I. Biologic effects of interferons. 1990;95:S66-S71.
21. Yamamura M, Modlin RL, Ohmen JD, Moh RL. Local expression of antiinflammatory cytokines in cancer. J Clin Invest 1993; 91:1005-10.
22. Dinney CPN, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res 1998;58:808-14.
23. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
24. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516-8.
25. Ricketts RR, Hatley RM, Corden BJ, Sabio H, Howell CG. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 1994;219:605-14.
26. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
27. Yancey KB, Smith JG. Interferon: status in treatment of skin disease. J Am Acad Dermatol 1980;3:585-95.
28. Shiell A. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma. Australas J Dermatol 1994;35:71-5.
29. De Silva SP, Dellon AL. Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study. J Surg Oncol 1985;28:72-4.